Ann: Change in substantial holding, page-25

It is a screaming buy.

Just check the broker playing with the price while the swap continues.
When one can observe such trading patterns for 6 months, has confirmation of two large off market transactions to a non connected
entity, clearly being a fund or very large investor, one can rest calmly knowing that with all updates being positive up to date, that
better days are on the horizon when company is less than 12 months away to be a clinical drug development company with
a possible drug delivery deal in 2022. The company is just collecting more data on kidney, CNS and other oculars to achieve
a maximum return for themselves and shareholders.
I recommend such behaviour.
The off market transfer and low price swaps avoid a CR at this points, which serves shareholders well as dilution is not necessary.

This stock will move when everybody is set. Biotech is the ultimate patience game with potential huge reward.
I would back this company on the science alone, our two US based directors, trading patterns, US presentations are just the indicators that the timing is right for 2022 additional to the research.

all IMO